{
  "@context": ["file://domain/_contexts/base.jsonld", "file://domain/_contexts/medicine.jsonld"],
  "@type": ["EducationalResource", "MedicalCondition"],
  "@id": "health-sciences:medicine:pulmonology:pulm-025",
  "metadata": {"version": "4.0.0", "created": "2026-01-09T01:51:20.000Z", "contributors": ["copilot-agent", "quality-enhancement-agent", "pulmonology-knowledge-base"], "confidence": 0.97, "status": "validated", "modified": "2026-01-11T20:40:00.000Z"},
  "classification": {"domain_path": "health-sciences/medicine/pulmonology", "type": "definition", "difficulty": "advanced", "importance": "high", "aku_id": "025", "keywords": ["aspergillosis", "Aspergillus", "invasive aspergillosis", "ABPA", "aspergilloma", "voriconazole", "immunocompromised"], "medical_specialty": "pulmonology", "clinical_context": "fungal_infections"},
  "content": {
    "title": "Aspergillosis",
    "summary": "Spectrum of pulmonary diseases caused by Aspergillus species, ranging from allergic (ABPA) to chronic (aspergilloma, CPA) to invasive forms depending on host immune status",
    "key_points": ["Aspergillus fumigatus is most common pathogen", "Disease spectrum depends on host immune status", "ABPA in asthmatics/CF - allergic response, IgE elevation, fleeting infiltrates", "Aspergilloma - fungus ball in preexisting cavity (TB, sarcoid)", "Invasive aspergillosis - immunocompromised (neutropenia, transplant, steroids)", "Diagnosis: Galactomannan antigen, beta-D-glucan, culture, BAL, biopsy", "Voriconazole is first-line for invasive; itraconazole for ABPA"],
    "statement": {"text": "Aspergillosis encompasses a spectrum of diseases caused by Aspergillus species (most commonly A. fumigatus). Allergic bronchopulmonary aspergillosis (ABPA) occurs in asthmatics and CF patients as a hypersensitivity reaction. Aspergilloma is a fungus ball colonizing a preexisting lung cavity. Chronic pulmonary aspergillosis (CPA) causes progressive lung destruction in immunocompetent hosts with structural lung disease. Invasive aspergillosis is a life-threatening infection in immunocompromised patients, particularly those with prolonged neutropenia. Voriconazole is first-line therapy for invasive disease.", "formal": "Aspergillosis spectrum = ABPA (allergic) | Aspergilloma (colonization) | CPA (chronic) | Invasive (immunocompromised)"},
    "explanation": {"intuition": "Aspergillus spores are everywhere in the environment - we inhale them daily without harm. What happens when spores reach the lungs depends on immune status. In allergic individuals, spores trigger an exaggerated immune response (ABPA). In those with lung cavities from old disease, spores can grow into a fungus ball without invading tissue. In the severely immunocompromised, Aspergillus invades blood vessels and tissue, causing life-threatening infection.", "key_insight": "The clinical manifestation is determined by the immune response: hypersensitivity (ABPA in allergic patients), saprophytic (aspergilloma in cavities), chronic destructive (CPA in structural disease), or invasive angioinvasive (neutropenic, transplant). Treatment differs markedly - steroids for ABPA, antifungals for invasive, surgery for aspergilloma with hemoptysis.", "technical_details": "Galactomannan is a cell wall component detectable in serum and BAL in invasive disease (sensitivity ~70% serum, ~85% BAL). Halo sign (ground-glass halo around nodule from hemorrhage) on CT is early finding of invasive aspergillosis. Voriconazole achieves better outcomes than amphotericin B for invasive disease. Isavuconazole is an alternative with fewer drug interactions."},
    "definitions_glossary": {"aspergillus": "Genus of ubiquitous molds; A. fumigatus most common human pathogen", "abpa": "Allergic bronchopulmonary aspergillosis; hypersensitivity reaction in asthma/CF patients", "aspergilloma": "Fungus ball colonizing preexisting pulmonary cavity; 'mobile mass' on imaging", "invasive_aspergillosis": "Tissue-invasive infection in immunocompromised; angioinvasive with high mortality", "chronic_pulmonary_aspergillosis": "Slowly progressive aspergillus infection in structural lung disease", "galactomannan": "Aspergillus cell wall polysaccharide; biomarker for invasive disease", "beta_d_glucan": "Pan-fungal cell wall marker; elevated in aspergillosis and other fungal infections", "halo_sign": "CT finding of ground-glass halo around nodule from hemorrhagic infarction", "air_crescent_sign": "CT finding as necrotic lesion cavitates during neutrophil recovery", "angioinvasion": "Fungal invasion of blood vessels causing thrombosis and infarction", "voriconazole": "Triazole antifungal; first-line for invasive aspergillosis", "itraconazole": "Triazole antifungal; used for ABPA and chronic aspergillosis"}
  },
  "clinical_features": {
    "pathophysiology": {"mechanism": "Aspergillus spores (conidia) are inhaled constantly. Normally, mucociliary clearance and alveolar macrophages eliminate them. In ABPA, spores trigger IgE-mediated and cell-mediated hypersensitivity in genetically susceptible hosts. In cavitary disease, spores germinate and form a fungus ball without tissue invasion. In neutropenia or severe immunosuppression, hyphae invade tissues and blood vessels, causing infarction and dissemination.", "disease_spectrum": {"abpa": "Th2 hypersensitivity; IgE elevation, eosinophilia, bronchiectasis", "aspergilloma": "Saprophytic colonization of preexisting cavity (TB, sarcoid, cavity)", "cpa": "Slowly progressive destruction in structural lung disease; cavitation over months-years", "invasive": "Angioinvasive infection in neutropenia, transplant, high-dose steroids; 30-50% mortality"}},
    "diagnostic_criteria": {"abpa": {"clinical": "Asthma or CF with worsening symptoms, central bronchiectasis", "labs": "Total IgE >1000, Aspergillus-specific IgE/IgG, eosinophilia, positive skin test", "imaging": "Fleeting infiltrates, mucoid impaction, central bronchiectasis"}, "invasive": {"at_risk": "Neutropenia >10 days, transplant, high-dose steroids, GVHD", "imaging": "Nodules, halo sign, air-crescent sign, cavitation", "biomarkers": "Galactomannan (serum/BAL), beta-D-glucan", "micro": "Culture, histopathology showing septate branching hyphae"}},
    "treatment_options": {"abpa": {"first_line": "Systemic corticosteroids (prednisone 0.5-1 mg/kg) for acute exacerbations", "steroid_sparing": "Itraconazole to reduce fungal burden and steroid dose", "biologics": "Omalizumab (anti-IgE) in refractory cases"}, "aspergilloma": {"observation": "If asymptomatic", "antifungals": "Itraconazole/voriconazole for chronic symptoms", "surgery": "Resection for recurrent hemoptysis, localized disease", "embolization": "Bronchial artery embolization for hemoptysis"}, "invasive": {"first_line": "Voriconazole 6mg/kg q12h x2 doses then 4mg/kg q12h", "alternatives": "Isavuconazole, liposomal amphotericin B, combination therapy", "duration": "Minimum 6-12 weeks; depends on response and immune recovery", "source_control": "Surgical resection if localized and surgically accessible"}}
  },
  "skos": {"prefLabel": {"@language": "en", "@value": "Aspergillosis"}, "altLabel": [{"@language": "en", "@value": "Aspergillus Infection"}, {"@language": "en", "@value": "Invasive Pulmonary Aspergillosis"}], "definition": {"@language": "en", "@value": "Spectrum of pulmonary diseases caused by Aspergillus species, ranging from allergic to invasive forms depending on host immune status"}, "notation": "pulm-025", "scopeNote": "Covers ABPA, aspergilloma, CPA, and invasive aspergillosis; includes diagnosis and treatment", "example": "A neutropenic leukemia patient develops fever, cough, and chest CT showing nodule with halo sign; galactomannan positive; started on voriconazole for invasive pulmonary aspergillosis"},
  "medicalCode": [{"@type": "MedicalCode", "codingSystem": "SNOMED-CT", "codeValue": "59702007", "uri": "http://snomed.info/id/59702007", "description": "Aspergillosis (disorder)", "matchType": "exactMatch"}, {"@type": "MedicalCode", "codingSystem": "ICD-10-CM", "codeValue": "B44.0", "description": "Invasive pulmonary aspergillosis", "matchType": "narrower"}, {"@type": "MedicalCode", "codingSystem": "MeSH", "codeValue": "D001228", "uri": "http://id.nlm.nih.gov/mesh/D001228", "description": "Aspergillosis", "matchType": "exactMatch"}],
  "pedagogical": {"target_audience": ["medical_students", "pulmonology_fellows", "infectious_disease_fellows", "critical_care_fellows", "oncology_fellows"], "estimated_time": "30min", "difficulty_curve": 0.7, "learning_objectives": ["Classify aspergillosis by host immune status and clinical presentation", "Diagnose invasive aspergillosis using clinical, imaging, and biomarker criteria", "Select appropriate antifungal therapy for each aspergillosis type", "Recognize ABPA in asthma and cystic fibrosis patients"], "clinical_pearls": ["Halo sign on CT in febrile neutropenic patient = think invasive aspergillosis", "ABPA = asthma + central bronchiectasis + high IgE + positive Aspergillus IgE/IgG", "Voriconazole is first-line for invasive; check trough levels (target 1-5 Î¼g/mL)", "Galactomannan most useful in neutropenic patients; less sensitive in non-neutropenic", "Aspergilloma in old TB cavity - 'ping pong ball' that moves with position", "Air crescent sign = good sign - means neutrophils recovering and forming cavity around necrotic lesion"], "board_yield": {"usmle_step1": "Moderate - fungal microbiology", "usmle_step2": "High - diagnosis and treatment by type", "infectious_disease_boards": "Very High - comprehensive aspergillosis management"}, "common_misconceptions": ["All aspergillosis needs antifungals (false - ABPA treated with steroids primarily)", "Positive sputum culture = disease (false - may be colonization; need clinical context)", "Amphotericin B is first-line for invasive (false - voriconazole preferred based on trials)"]},
  "relationships": {"prerequisites": [{"id": "urn:wskg:medicine:infectious-disease:fungal-infections", "title": "Fungal Infections Overview", "strength": 0.85}], "skos:broader": [{"@id": "urn:wskg:medicine:pulmonology:fungal-lung-infections", "@type": "skos:Concept", "skos:prefLabel": "Fungal Lung Infections"}], "owl:sameAs": ["http://snomed.info/id/59702007", "http://www.wikidata.org/entity/Q727879"], "skos:exactMatch": ["http://snomed.info/id/59702007", "http://id.nlm.nih.gov/mesh/D001228"]},
  "provenance": {"verification_status": "verified", "last_verified": "2026-01-11T20:40:00.000Z", "sources": [{"source": "Patterson TF, et al. Practice Guidelines for the Diagnosis and Management of Aspergillosis. Clin Infect Dis. 2016;63:e1-e60", "type": "clinical_guideline", "year": 2016, "doi": "10.1093/cid/ciw326", "confidence": 1.0, "relevance": "IDSA aspergillosis guidelines"}, {"source": "Murray and Nadel's Textbook of Respiratory Medicine, 7th ed. Elsevier 2022", "type": "textbook", "year": 2022, "isbn": "978-0323655873", "confidence": 0.95}]},
  "quality_assessment": {"CQS": 0.93, "completeness": 0.94, "accuracy": 0.96, "clarity": 0.91, "pedagogical_quality": 0.91, "ontology_alignment": 0.93, "last_assessment": "2026-01-11T20:40:00.000Z", "assessor": "quality-enhancement-agent"},
  "rendering_hints": {"primary_representation": "definition_with_spectrum_table", "show_images": true, "visualization": ["aspergillosis_spectrum", "halo_sign_ct", "treatment_algorithm"]},
  "owl:sameAs": "http://dbpedia.org/resource/Aspergillosis",
  "skos:exactMatch": "http://www.wikidata.org/entity/Q727879"
}